|
Market Closed -
NYSE
16:00:03 2026-08-31 EDT
|
5-day change | 1st Jan Change | ||
| 1.170 USD | +2.63% |
|
+17.40% | -66.86% |
| 08-14 | ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says | MT |
| 08-13 | ADC Therapeutics SA, Q2 2026 Earnings Call, Aug 13, 2026 |
Company Valuation: ADC Therapeutics SA
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 1,550 | 306.9 | 134.1 | 192.4 | 437.3 | 145.5 | - | - |
| Change | - | -80.2% | -56.31% | 43.49% | 127.27% | -66.72% | - | - |
| Enterprise Value (EV) | 1,092 | 90.22 | -20.12 | 192.4 | 437.3 | 145.5 | 145.5 | 145.5 |
| Change | - | -91.74% | -122.31% | 1,056.12% | 127.27% | -66.72% | 0% | 0% |
| P/E | -6.73x | -1.93x | -0.56x | -1.23x | -3.15x | -1.54x | -1.73x | -4.46x |
| PBR | 9.34x | 3.49x | - | - | - | - | - | - |
| PEG | - | 0.1x | -0x | 0x | 0.1x | 0x | 0.2x | 0.1x |
| Capitalization / Revenue | 45.7x | 1.46x | 1.93x | 2.72x | 5.37x | 1.8x | 1.43x | 0.81x |
| EV / Revenue | 0x | 0x | -0x | 0x | 0x | 1.8x | 1.43x | 0.81x |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | -0x | -0x | 0x | -0x | -0x | -1.57x | -2.28x | 34.7x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -3 | -1.99 | -2.94 | -1.62 | -1.12 | -0.76 | -0.6775 | -0.2625 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 33.92 | 209.9 | 69.56 | 70.84 | 81.36 | 80.65 | 102 | 179.7 |
| EBITDA | -198.6 | -71.98 | - | - | - | - | - | - |
| EBIT 1 | -261.7 | -123.6 | -166 | -130.7 | -121.5 | -92.62 | -63.87 | 4.196 |
| Net income 1 | -230 | -155.8 | -240.1 | -157.8 | -142.6 | -119.9 | -117.8 | -50.52 |
| Net Debt | -458.5 | -216.7 | -154.2 | - | - | - | - | - |
| Reference price 2 | 20.200 | 3.840 | 1.660 | 1.990 | 3.530 | 1.170 | 1.170 | 1.170 |
| Nbr of stocks (in thousands) | 76,754 | 79,934 | 80,781 | 96,690 | 123,877 | 127,668 | - | - |
| Announcement Date | 3/3/22 | 2/28/23 | 3/13/24 | 3/27/25 | 3/10/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.5x | - | - | - | 146M | |
| 20.59x | 7.25x | 14.66x | 1.42% | 69.54B | |
| 36.89x | 9.62x | 29.41x | 0.04% | 64.97B | |
| 30.69x | 6.58x | 17.2x | -.--% | 26.51B | |
| -72.56x | 13.98x | -67.43x | -.--% | 25.89B | |
| -15.61x | 5.94x | -7.46x | -.--% | 25.64B | |
| 58.27x | 21.67x | 43.95x | 0.26% | 20.22B | |
| 27.27x | 5.11x | 16.98x | -.--% | 19.98B | |
| 1415.29x | 39.34x | 858.54x | -.--% | 15.69B | |
| 16.84x | 5x | 11.66x | -.--% | 13.49B | |
| Average | 151.62x | 12.72x | 101.95x | 0.19% | 28.21B | |
| Weighted average by Cap. | 93.99x | 10.79x | 57.82x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- ADCT Stock
- Valuation ADC Therapeutics SA
Select your edition
All financial news and data tailored to specific country editions
